Dr David Berglund and Dr David Wooding nominated as new board members at XNK Therapeutics
STOCKHOLM, Sept. 15, 2021 /PRNewswire/ -- -- September 15, 20, 2022 -- SHOCKTOLM - Sept 15:20 p.m. XNK Therapeutics AB announced today that Dr. David Berglund and Dr Dr Stephen Wooding are expected to be appointed members of the board of directors. The decision will be made at an extra general meeting on October 4 and a notice will also be sent separately.
We are incredibly pleased to be able to attract such dedicated life science professionals like David and Stephen to the board. "They will definitely add valuable knowledge to XNK," said Lena Degling Wikingsson, Chairman of the board.
Dr. Berglund, M.D., Ph. D. and B.A. is a professor of Immunology at Uppsala University. He has published more than 40 peer-reviewed articles in s David received clinical training in plastic surgery and transplant surgery at Uppsala and Karolinska University in Sweden.
He has worked with drug development for over ten years focusing on strategic leadership questions both early- and late-stage pharmaceutical companies. David is a graduate of the NYU Stern School of Business with specializations in Corporate Finance, Leadership and Change Management.
Dr. Wooding, MB, long career in science, helping patients develop new technologies through the drug development process. He has spent nearly three decades in Johnson's pharmaceutical division Janssen. He started working in R&D and finally became a leadership player at the commercial/R&P interface, as he joined Janssen's global senior leadership team.
He qualified in medicine at the London University Hospital, where he then joined the pharmaceutical industry, eventually gaining experience in R&D and then broadening his experience to become a commercial and ultimately help shape plethora Dr. Wooding is the actual principal of Edipol Pharmaceutical Consulting Ltd, with the help of two start-ups as Chief Scientific Officer.
"I'm pleased to announce my nomination for the board of XNK Therapeutics. The company is uniquely positioned to deliver transformative cell-based therapies to multi-sector and other unmet needs. Dr. Berglund said that I am excited to join the company at this important stage of development.
Dr. Wooding said that it's an honor to be asked to join the XNK board. The company is patient-focused and determined to use very scientific scientific techniques to improve patient outcomes. I look forward to helping you to that mission.
Gunnar Mattsson, who has been director of XNK since 2012, is set to be elected new chairman at the extra general meeting. Lena Degling Wikingsson, current chairman, is going to be on board as a member.
For more information, please contact: Johan Liwing, CEO, XNK TherapeuticsTel: +46 706 70 36 75E-mail: [email protected]
About XNK Therapeutics AB About Us About KNK Pharmaceuticals About GROUP.
XNK Therapeutics is a clinical-stage immunotherapy company that focuses its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company's platform technology and leading investigational drug candidate are ideal targets for cancers, including settings where allogeneic cell products aren't readily available. It's likely that the product will be crucial to tomorrow'' cancer treatment strategy. XNK Therapeutics is headquartered in Sweden. For more information, visit www.xnktherapeutics.com.
Cision has presented this information to you from http://news.cision.com. Cisision - http/news/.
There are three files for download: a CD, and XX, if you don't.
SOURCE XNK Therapeutics AB STRICE, SK & NABs Therapeutic BV - ADD.